Although both SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists were reported to reduce all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, and renal failure, SGLT2 inhibitors reduced mortality and hospitalization caused by HF more frequently than glucagon-like peptide-1 receptor agonists.46 The gene discussed is GLP1R; the disease is kidney failure.